These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Monensin inhibits glioblastoma angiogenesis via targeting multiple growth factor receptor signaling. Wan W; Zhang X; Huang C; Chen L; Yang X; Bao K; Peng T Biochem Biophys Res Commun; 2020 Sep; 530(2):479-484. PubMed ID: 32595038 [TBL] [Abstract][Full Text] [Related]
48. Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. Moreno MJ; Ball M; Andrade MF; McDermid A; Stanimirovic DB Glia; 2006 Jun; 53(8):845-57. PubMed ID: 16586492 [TBL] [Abstract][Full Text] [Related]
49. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648 [TBL] [Abstract][Full Text] [Related]
50. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Onishi M; Kurozumi K; Ichikawa T; Date I Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241 [TBL] [Abstract][Full Text] [Related]
51. Antiangiogenic therapies for glioblastoma. Arrillaga-Romany I; Norden AD CNS Oncol; 2014; 3(5):349-58. PubMed ID: 25363007 [TBL] [Abstract][Full Text] [Related]
52. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Weller M; Yung WK Neuro Oncol; 2013 Aug; 15(8):971. PubMed ID: 23864129 [No Abstract] [Full Text] [Related]
53. Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations. Nery de Albuquerque Rego G; da Hora Alves A; Penteado Nucci M; Bustamante Mamani J; Anselmo de Oliveira F; Gamarra LF Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599834 [TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter? Pellerino A; Bruno F; Soffietti R; Rudà R Curr Oncol Rep; 2023 Jul; 25(7):777-785. PubMed ID: 37071295 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. Boult JKR; Box G; Vinci M; Perryman L; Eccles SA; Jones C; Robinson SP Neoplasia; 2017 Sep; 19(9):684-694. PubMed ID: 28780387 [TBL] [Abstract][Full Text] [Related]
56. Angiogenesis and antiangiogenic therapy for malignant gliomas. Takano S; Kamiyama H; Tsuboi K; Matsumura A Brain Tumor Pathol; 2004; 21(2):69-73. PubMed ID: 15700836 [TBL] [Abstract][Full Text] [Related]
57. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Verhoeff JJ; Stalpers LJ; Claes A; Hovinga KE; Musters GD; Peter Vandertop W; Richel DJ; Leenders WP; van Furth WR Eur J Cancer; 2009 Nov; 45(17):3074-80. PubMed ID: 19734041 [TBL] [Abstract][Full Text] [Related]
58. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Lucio-Eterovic AK; Piao Y; de Groot JF Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589 [TBL] [Abstract][Full Text] [Related]
59. A vasculature-centric approach to developing novel treatment options for glioblastoma. Wirsching HG; Roth P; Weller M Expert Opin Ther Targets; 2021 Feb; 25(2):87-100. PubMed ID: 33482697 [No Abstract] [Full Text] [Related]
60. Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far. Clavreul A; Pourbaghi-Masouleh M; Roger E; Menei P Int J Nanomedicine; 2019; 14():2497-2513. PubMed ID: 31040671 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]